Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROMEO: Long-term Safety of Tozorakimab in COPD
NCT07566195Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started May 2026; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07566195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566195.